SRR2016975
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.260
- PANCREAS_BETA_CELLS+0.190
- KRAS_SIGNALING_DN+0.170
- MYC_TARGETS_V2+0.170
- XENOBIOTIC_METABOLISM+0.100
- ALLOGRAFT_REJECTION+0.090
- HEME_METABOLISM+0.090
- APOPTOSIS+0.070
Top 10 suppressed
- ANDROGEN_RESPONSE-0.330
- G2M_CHECKPOINT-0.330
- PROTEIN_SECRETION-0.290
- WNT_BETA_CATENIN_SIGNALING-0.290
- E2F_TARGETS-0.280
- MITOTIC_SPINDLE-0.260
- NOTCH_SIGNALING-0.250
- KRAS_SIGNALING_UP-0.210
- COMPLEMENT-0.200
- ANGIOGENESIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016951 | — | — | 0.763 |
| 2 | s0112210 | — | — | 0.746 |
| 3 | SJEPD001512_D1.RNA-Seq | EPN | Supratentorial EPN | 0.720 |
| 4 | TCGA-BH-A0BT-01A-11R-A12P-07 | — | B | 0.717 |
| 5 | SJEPD027_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.695 |
| 6 | TCGA-CV-A461-01A-41R-A266-07 | — | — | 0.688 |
| 7 | EPT0505 | EPN | EPN Tumor | 0.680 |
| 8 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.674 |
| 9 | 399e5b76-1d8d-4db9-a186-ffdc2f6e0884 | — | — | 0.671 |
| 10 | MNG569 | — | — | 0.670 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.070 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |